Generali Asset Management SPA SGR Invests $2.35 Million in Edwards Lifesciences Co. (NYSE:EW)

Generali Asset Management SPA SGR purchased a new position in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 31,741 shares of the medical research company’s stock, valued at approximately $2,350,000.

A number of other institutional investors also recently made changes to their positions in EW. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $30,000. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences during the third quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,303 shares of company stock worth $3,715,776. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.7 %

NYSE:EW opened at $70.87 on Thursday. The stock’s 50 day moving average price is $71.54 and its 200 day moving average price is $70.35. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $41.66 billion, a P/E ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on EW shares. Truist Financial reissued a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Citigroup increased their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.